Infant Bacterial Therapeutics AB (publ) Market Cap ($105.07 Million)
Market Cap & Net Worth: Infant Bacterial Therapeutics AB (publ) (IBT-B)
Infant Bacterial Therapeutics AB (publ) market cap. Infant Bacterial Therapeutics AB (publ) (ST:IBT-B) has a market capitalization of $105.07 Million (Skr976.36 Million) as of November 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #18810 globally and #325 in its home market, demonstrating a -0.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Infant Bacterial Therapeutics AB (publ)'s stock price Skr75.00 by its total outstanding shares 13018137 (13.02 Million). Also see IBT-B cash flow conversion for how efficiently the company converts equity into cash flow.
Infant Bacterial Therapeutics AB (publ) Market Cap History (2016–2026)
Infant Bacterial Therapeutics AB (publ) market cap history from 2016 to 2026. Data shows growth from $55.17 Million to $105.07 Million (2.38% CAGR). Check Infant Bacterial Therapeutics AB (publ) (IBT-B) share price today for real-time trading data and today's change.
Infant Bacterial Therapeutics AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Infant Bacterial Therapeutics AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Infant Bacterial Therapeutics AB (publ) growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
18772.86x
Infant Bacterial Therapeutics AB (publ)'s market cap is 18772.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $55.17 Million | $162.00K | -$38.11 Million | 340.57x | N/A |
| 2017 | $161.11 Million | $238.00K | -$36.16 Million | 676.93x | N/A |
| 2022 | $70.05 Million | $12.00K | -$65.45 Million | 5837.33x | N/A |
| 2023 | $126.09 Million | $77.00K | -$123.07 Million | 1637.49x | N/A |
| 2024 | $75.09 Million | $4.00K | -$136.91 Million | 18772.86x | N/A |
Competitor Companies of IBT-B by Market Capitalization
Companies near Infant Bacterial Therapeutics AB (publ) in the global market cap rankings as of November 4, 2026. Also see Infant Bacterial Therapeutics AB (publ) total assets for a full breakdown of the balance sheet.
Key companies related to Infant Bacterial Therapeutics AB (publ) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Infant Bacterial Therapeutics AB (publ) (2016–2026)
Market capitalization of Infant Bacterial Therapeutics AB (publ) from 2016 to today. Between 2016 and today, Infant Bacterial Therapeutics AB (publ)'s market cap moved from $55.17 Million to $ 105.07 Million, with a yearly change of 2.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr105.07 Million | +48.51% |
| 2025 | Skr70.75 Million | -5.78% |
| 2024 | Skr75.09 Million | -40.44% |
| 2023 | Skr126.09 Million | +80.00% |
| 2022 | Skr70.05 Million | -25.15% |
| 2021 | Skr93.58 Million | -40.36% |
| 2020 | Skr156.91 Million | -21.68% |
| 2019 | Skr200.34 Million | +1.06% |
| 2018 | Skr198.24 Million | +23.04% |
| 2017 | Skr161.11 Million | +192.01% |
| 2016 | Skr55.17 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Infant Bacterial Therapeutics AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $105.07 Million USD |
| MoneyControl | $105.07 Million USD |
| MarketWatch | $105.07 Million USD |
| marketcap.company | $105.07 Million USD |
| Reuters | $105.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also develop… Read more